lomustine / Generic mfg. - LARVOL DELTA

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma. (PubMed, J Clin Oncol) - P3 | "Clinically meaningful improvements were observed; eflornithine + lomustine doubled PFS and improved OS in patients with recurrent IDH-mutant, grade 3 astrocytoma, but not grade 4 tumors, after prior radiotherapy and TMZ, consistent with its cytostatic mechanism of action."

Journal • P3 data • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

A genomically-tailored multi-agent precision medicine clinical trial for adults with recurrent glioblastoma. (PubMed, Clin Cancer Res) - "Implementation of individualized treatment regimens in a timely fashion was feasible for patients with surgically resectable rGBM. Overall efficacy was not significantly improved compared to a contemporary patient cohort treated without experimental regimens, with full dosing of most combination therapies limited by toxicities."

Journal • Astrocytoma • Brain Cancer • Glioblastoma • Hematological Disorders • Oncology • Solid Tumor

GBM AGILE Platform trial for newly diagnosed and recurrent GBM: Results of first experimental arm, regorafenib (EANO 2024) - P2/3 | "Control is temozolomide (ND) and lomustine (RD). GBM AGILE efficiently and compellingly addressed regorafenib’s role in GBM, in RD and NDU. These findings are germane as they fail to confirm the REGOMA results in RD. GBM AGILE continues to efficiently assess other therapies, including utilizing concurrent and previously accrued controls."

Glioblastoma • Oncology

COMPARISON OF CARMUSTINE-, LOMUSTINE-, AND NITROSOUREA-FREE CONDITIONING REGIMENS FOR AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN LYMPHOMA: RESULTS FROM THE BRAZILIAN REGISTRY (EBMT 2026) - "In this large national cohort, outcomes after auto-HCT for lymphoma were comparable across carmustine-, lomustine-, and nitrosourea-free conditioning regimens, supporting their interchangeability when specific agents are unavailable"

B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation

COULD PROPHYLACTIC NASOGASTRIC TUBE FEEDING REDUCE WEIGHT LOSS FOR PATIENTS UNDERGOING HIGH-TOXICITY CONDITIONING REGIMENS DURING AUTOLOGOUS STEM CELL TRANSPLANT? (EBMT 2026) - " Three hundred and eighty four patient were included, 60% male, median age 58 years, 69% had multiple myeloma, 21% Non-Hodgkin lymphoma, 51% were conditioned with melphalan 200, 20% with L(B)EAM (lomustine or carmustine with cytarabine, etoposide and melphalan), 19% with melphalan 140, 10% with TT-BNCU (thiotepa and carmustine). Haematological cancer patients undergoing auto-SCT with TT-BNCU or L(B)EAM conditioning regimens are at significantly higher risk of early weight loss and longer hospital stay compared to those receiving melphalan 200 and 140. These results highlight a potential role for prophylactic nasogastric tube feeding in patients receiving high-toxicity regimens to minimise unintentional weight loss and support nutritional recovery throughout auto-SCT to reduce length of stay. Further prospective research is warranted to evaluate the feasibility, safety and long-term impact of prophylactic nasogastric tube feeding in patients receiving high-toxicity..."

Clinical • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Transplantation

ImproveCodel: A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). (clinicaltrials.gov) - P3 | N=406 | Recruiting | Sponsor: University Hospital Heidelberg | Trial completion date: Mar 2031 ➔ Mar 2033 | Trial primary completion date: Mar 2031 ➔ Mar 2033

HEOR • Trial completion date • Trial primary completion date • Brain Cancer • Glioma • Hematological Disorders • Oligodendroglioma • Oncology • Solid Tumor

NRG-BN011: Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma (clinicaltrials.gov) - P3 | N=306 | Suspended | Sponsor: NRG Oncology | Recruiting ➔ Suspended

Trial suspension • Brain Cancer • Glioblastoma • Gliosarcoma • Oncology • Sarcoma • Solid Tumor • IDH1 • MGMT

Cytotoxicity of Cannabinoids in Combination with Traditional Lymphoma Chemotherapeutic Drugs Against Non-Hodgkin's Lymphoma. (PubMed, Biomedicines) - "The purpose of this study was to establish the cytotoxic effect of cannabinoids in combination with the components of CHOP and lomustine. This traditional NHL chemotherapy regimen comprises cyclophosphamide, doxorubicin, vincristine, and prednisolone... Our results demonstrate that the cytotoxic effects of all traditional NHL chemotherapy drugs are synergistically enhanced (interaction with CI < 1) by each of the three cannabinoids at sub-IC50 concentrations. This work provides a proof of concept for using cannabinoids and traditional NHL drugs in combination to reduce the dose, and thereby potentially reducing the toxicity, of chemotherapeutic drugs and increasing the survival benefit in lymphoma clinical translation studies, offering a significant advancement in cancer treatment."

Journal • Anorexia • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pain • Palliative care

Case Report: Primary intestinal histiocytic sarcoma in a cat. (PubMed, Front Vet Sci) - "The patient underwent surgical excision via enterectomy, followed by adjuvant lomustine chemotherapy, achieving complete remission. Despite transient chemotherapy-induced myelosuppression, the cat remains alive and disease-free 2 years after diagnosis. This case highlights the importance of combining imaging, histopathology, and IHC when diagnosing feline intestinal masses."

Journal • Oncology • Sarcoma • Solid Tumor • IRF4 • KIT • MSR1

Efficacy and biomarker analysis of phase 2 (P2) and window-of-opportunity (WoO) cohorts of patients with recurrent glioblastoma (rGBM) treated with ST101, an inhibitor of the transcription factor C/EBPβ. (ASCO 2024) - P1/2 | "Monotherapy ST101 in pts with rGBM has an excellent safety profile and results in comparable outcomes to current 2 nd line treatments. ST101 crosses the BBB, engages its target, and potentially induces treatment-related necrosis. These encouraging clinical activity, safety, and tissue findings, as well as preclinical data showing additive activity in combination with lomustine, support advancing ST101 to a randomized, placebo-controlled study comparing ST101 + lomustine vs."

Biomarker • Clinical • P2 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma. (ASCO 2024) - P2/3 | "C is temozolomide (in ND) & lomustine (in RD). GBM AGILE is an efficient & effective model for phase 3 drug development. VAL did not increase OS compared to C in any glioblastoma subtype. GBM AGILE evaluated this agent in less time, at lower cost, & with fewer patients than typical registration trials & is currently evaluating several other arms."

P3 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study. (PubMed, Trials) - P3 | "EORTC-2227-BTG (LEGATO) is a publicly funded pragmatic phase III trial designed to clarify the efficacy of adding reirradiation to chemotherapy with lomustine for the treatment of patients with first progression of glioblastoma."

Clinical protocol • Journal • P3 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. (PubMed, J Clin Oncol) - P2/3 | "This study is the first to report the predictive value of the WHO-defined diagnostic classification in a set of uniformly treated patients with LGG in a clinical trial. Importantly, this post hoc analysis supports the notion that patients with IDH-mutant high-risk LGG regardless of codeletion status receive benefit from the addition of PCV."

Journal • P3 data • Glioma • Oncology • Solid Tumor • IDH1

PHASE 3 STELLAR STUDY SHOWS EFLORNITHINE IMPROVES OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH RECURRENT 2021 WHO ASTROCYTOMA, IDH-MUTANT GRADE 3 (SNO 2024) - "STELLAR was a phase III randomized, open-label trial of eflornithine (ornithine decarboxylase inhibitor) with lomustine versus lomustine alone, originally for patients with recurrent AA. However, as the WHO definition of AA evolved during trial conduct (e.g., excluding IDH wild-type disease), we determined results in both the original ITT population and by revised molecularly defined WHO 2021 diagnoses in pre-planned analyses .METHOD Key eligibility: age ≥ 18, AA (2016 WHO criteria), first recurrence ≥ 6 months after radiation and temozolomide, KPS ≥ 70, no imaging findings consistent with grade 4 glioblastoma...CONCLUSION There was no difference in OS between arms in the ITT analysis. However, medically meaningful and statistically significant OS and PFS benefits were observed with eflornithine in the pre-planned analysis of patients with molecularly defined 2021 WHO CNS grade 3 astrocytoma."

Clinical • Late-breaking abstract • P3 data • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Venous Thromboembolism and Bleeding with Temozolomide-, Bevacizumab-, and Nitrosourea-Based Therapy in Glioma: A Dual-Database Pharmacovigilance Study. (PubMed, Cancers (Basel)) - "This study used large spontaneous reporting databases to compare VTE, central nervous system (CNS) bleeding and gastrointestinal (GI) bleeding signals associated with four representative systemic therapies for glioma-temozolomide, bevacizumab and the nitrosourea alkylating agents lomustine and carmustine-and explore bevacizumab-based combination regimens. Bevacizumab + temozolomide regimens had higher RORs for VTE and GI bleeding than bevacizumab alone, while bevacizumab + lomustine showed only modest VTE increases and no robust bleeding signals. In real-world pharmacovigilance data, bevacizumab-containing therapy, particularly when combined with temozolomide, carries the greatest disproportionate burden of VTE and GI bleeding among common systemic treatments for malignant glioma, whereas temozolomide alone appears largely neutral, and current evidence supporting nitrosourea-related signals remains inconclusive."

Adverse events • Journal • Brain Cancer • Cardiovascular • Gastroenterology • Glioma • High Grade Glioma • Oncology • Solid Tumor • Venous Thromboembolism

Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG (clinicaltrials.gov) - P2 | N=130 | Active, not recruiting | Sponsor: Theodore S. Johnson | Recruiting ➔ Active, not recruiting | Trial primary completion date: Oct 2025 ➔ Aug 2026

Enrollment closed • Trial primary completion date • Brain Cancer • Diffuse Intrinsic Pontine Glioma • Ependymoma • Glioblastoma • Glioma • Medulloblastoma • Oncology • Pediatrics • Solid Tumor

Comparison of Diagnostic Utilities in a Canine Retrobulbar Large B-Cell Lymphoma With Multifocal Involvement. (PubMed, Vet Med Sci) - "Chemotherapy with l-asparaginase, vincristine, cyclophosphamide, doxorubicin and prednisone was initiated; however, neurological symptoms developed after the first cycle. Subsequent cerebrospinal fluid cytology and flow cytometry suggested central nervous system involvement in the lymphoma, and the dog was euthanized owing to disease progression despite the addition of lomustine. To our knowledge, this is the first report of bilateral retrobulbar large B-cell lymphoma with multifocal involvement in a dog. A comprehensive assessment of diagnostic modalities is essential to diagnose extranodal lymphoma and assess extranodal involvement."

Journal • B Cell Lymphoma • CNS Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Ophthalmology • CD21 • CD34 • CD5 • CD79A • CD8

Treatment strategies and innovation for recurrent high-grade glioma. (PubMed, J Neurooncol) - "Despite poor overall outcomes, incremental progress across targeted, immune, and delivery-based approaches supports a patient centered strategy emphasizing clinical-trial enrollment, molecular profiling and symptom focused care."

IO biomarker • Journal • Review • Brain Cancer • Diffuse Midline Glioma • Glioblastoma • Glioma • High Grade Glioma • Oncology • Solid Tumor • BRAF • NTRK

Recurrent Hematological Toxicity After Second-Line Treatment in Patients with Glioblastoma: Indication of a Potential Predisposition. (PubMed, Oncologist) - "First-line myelotoxicity for glioblastoma predicts its recurrence and earlier onset in second-line therapy. Patients with toxicity in first-line have an increased risk of severe hematological toxicity upon re-exposure. Lomustine carries a higher risk for myelotoxicity than temozolomide. These findings suggest an inherent predisposition to alkylating chemotherapy-induced myelotoxicity for a subgroup of patients. Integrating prior myelotoxicity history into second-line treatment decisions may improve risk stratification and guide monitoring."

Journal • Brain Cancer • Glioblastoma • Hematological Disorders • Oncology • Solid Tumor

Checkpoint inhibitors improve progression free survival after autologous transplant despite poorer pre-transplant response (ASH 2025) - "Introduction The checkpoint inhibitors (CI) nivolumab and pembrolizumab which target PD1 are established treatments for relapsed/refractory classic Hodgkin Lymphoma (cHL)...44 received brentuximab vedotin (BV)...All patients were conditioned with LEAM (lomustine, etoposide, cytarabine, melphalan)...CI treatment prior to ASCT may alter cHL disease biology leading to increased sensitization to subsequent high dose cytotoxic chemotherapy although more exploratory data assessing the mechanism is needed. We are planning a multi-centre analysis to investigate further."

Checkpoint inhibition • Pre-transplantation • Cardiovascular • Classical Hodgkin Lymphoma • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Metabolic Disorders • Oncology • Pneumonia • Transplantation

Comparing Isocitrate Dehydrogenase Inhibitors with Procarbazine, Lomustine, and Vincristine Chemotherapy for Oligodendrogliomas. (PubMed, Cancers (Basel)) - "IDH inhibitors such as vorasidenib have demonstrated promising efficacy and more favorable tolerability profiles, but a paucity of comparative data across therapeutic classes limits optimal treatment decision-making. Prospective head-to-head trials are essential for defining the optimal therapeutic sequence in this evolving treatment landscape. In the interim, we provide a recommend approach for current use."

Journal • Review • Brain Cancer • Glioma • Hematological Disorders • Oligodendroglioma • Oncology • Solid Tumor

An atlas of ex vivo drug sensitivity profiles in 666 clinical glioblastoma samples revealed distinct survival-associated networks (SNO 2025) - P=N/A | "Eleven drugs were tested, including DNA-damaging agents (lomustine, carboplatin, temozolomide, procarbazine, irinotecan, etoposide) and targeted agents (abemaciclib, dabrafenib, osimertinib, rucaparib, trametinib). Longitudinal sampling revealed dynamic changes in drug sensitivity, reflecting evolutionary tumor biology. This ex vivo drug sensitivity atlas reveals distinct, non-random survival-associated clustering patterns that reflect underlying glioblastoma cellular physiologies and may inform future clinical trial designs."

Preclinical • Brain Cancer • Glioblastoma • Glioma • Solid Tumor

Assessment of 18F-FET PET-based response to bevacizumab-based regimens in patients with glioblastoma at relapse using the PET RANO 1.0 criteria (SNO 2025) - "All patients (i) received bevacizumab in combination with a second agent (irinotecan, lomustine, or nivolumab), (ii) underwent MRI- and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET imaging at baseline and at a median time of 8 weeks (range, 4-12 weeks) after treatment initiation, and (iii) had available PET-derived parameters, i.e., metabolic tumor volume (MTV), maximum and mean tumor-to-brain ratios (TBRmax and TBRmean). PET RANO 1.0 criteria appear to be effective in predicting response to bevacizumab-based therapy in glioblastomas at relapse."

Clinical • Brain Cancer • Glioblastoma • Solid Tumor

Identifying common transcriptional mechanisms in treatment-resistant glioma. (SNO 2025) - "Background: Glioma, the most common primary brain tumor, shows poor prognosis and resistance to first-line therapies, like temozolomide (TMZ), lomustine (LOM) and panobinostat-marizomib (PM), complicating treatment and diminishing disease-free survival. RNA-sequencing identified common genes linked to TMZ, LOM, and PM chemoresistance, revealing key genetic networks involved in acquiring and maintaining drug resistance. Targeting these pathways, along with epigenetic silencing and/or combinatorial therapies, may resensitize chemoresistant cells and allow for effective treatment of glioma."

Brain Cancer • Glioma • High Grade Glioma • Solid Tumor • ERBB4 • FOXA1 • PDGFRA • SOX2

Scalable Tracking of Symptoms in the Electronic Health Record using Large Language Models in Patients with Central Nervous System Cancers Undergoing Therapy (SNO 2025) - "We applied the LLM to an external dataset of 51,541 notes representing 1,642 patients seen in neuro-oncology clinic (1/2018 to 12/2023) to obtain real-world symptom prevalence for temozolomide, bevacizumab, lomustine, immune checkpoint inhibitors (ICI), and methotrexate. In conclusion, LLMs offer the ability to scale symptom extraction from health records, which is crucial to understand symptom burden and power symptom-related interventions and studies in real-world patient cohorts."

Clinical • Brain Cancer • CNS Tumor • Constipation • Gastroenterology • Gastrointestinal Disorder • Mood Disorders • Oncology